No abstract

OBJECTIVE:To investigate the effects of the noncytotoxic drug (cyclooxygenase-2 (COX-2) inhibitor and octreotide) on growth of the multidrug-resistant human gastric carcinoma cell line SGC-7901/ADR. METHODS:The effects of non-cytotoxic drug on the growth of SGC-7901 and SGC-7901/ADR cells were evaluated by 3 H-thymidine incorporation assay. The apoptosis of cells was measured by the TdT-mediated dUTP nick end-labeling assay (TUNEL) and flow cytometric assay. Western blotting was used to analysis the expression of cyclooxygenase (COX-2) protein in SGC-7901 cells and SGC-7901/ADR cells and P-glycoprotein (P-gp) from SGC-7901/ADR cells with variable treatments. Activator protein-1 binding activity was examined by electrophoretic mobility shift assay. RESULTS:3 H-thymidine incorporation into SGC-7901/ADR cells treated with celecoxib was significantly lower than that of control group (471.3 ± 79.7 cpm vs 917.5 ± 130.8 cpm, P < 0.05). When combined with octreotide, celecoxib presented lower 3 H-thymidine incorporations than its used alone and decreased to 53.3% of that amount original. Either celecoxib or the combination group markedly induced apoptosis in SGC-7901/ADR cells. COX-2 protein in the SGC-7901/ ADR cells was higher than in that of the SGC-7901 cells (1.543 ± 0.052 vs 0.564 ± 0.021, P < 0.05). The inhibition of P-gp could be achieved with celecoxib alone and combination with octreotide (0.486 ± 0.012, 0.252 ± 0.014 vs 0.941 ± 0.033, P < 0.05). Moreover, AP-1 binding activity could be suppressed by noncytotoxic drug and showed a synergistic effect. CONCLUSION:The combination of non-cytotoxic drug significantly improved the inhibitive effects on the growth of multidrug-resistant human gastric cancer cells.

No abstract